Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-interferon - ribavirin in daily practice

Annals of Hepatology

Volumn 9, Issue 1, 2010, Pages 46-51

  Ridruejo, Ezequiel ^a   Adrover, Raúl ^b   Cocozzella, Daniel ^b   Fernández, Nora ^c   Reggiardo, María Virginia ^d  

^a CEMIC   (Argentina)

^b Centro de la Provincia de Buenos Aires National University   (Argentina)

^c HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^d Rosario Prov de Santa Fe   (Argentina)

Author keywords

Daily practice; HCV; Pegylated interferon alfa; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ADULT; ANEMIA; ARGENTINA; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; NEUTROPENIA; RECOMMENDED DRUG DOSE; SUICIDAL IDEATION; THROMBOCYTOPENIA; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; CLINICAL TRIAL; DRUG COMBINATION; DRUG TOXICITY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; ARGENTINA; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77952736675     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31678-3     Document Type: Article

References (23)

1. Anonymous. Recommendations from the National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002; 36: s3-s20.
2. Asociación Argentina para el Estudio de las Enfermedades del Hígado. Consenso Argentino de Hepatitis C; 2007.
3. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
4. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
5. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-?2a and Ribavirin Combination Therapy in Chronic Hepatitis C. A Randomized Study of Treatment Duration and Ribavirin Dose. Ann Intern Med 2004; 140: 346-355.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterfe-ron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
8. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how they get there? Ann Intern Med 2002; 137: 10-16.
9. Diago M, Olveira A, Solá R, et al. Treatment of chronic hepatitis C genotype 1 with peginterferon-alpha 2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. Aliment Pharmacol Ther 2007; 25: 899-906.
10. Piai G, Scalice E, Focareta R, et al. From trials to a real hospital setting: effectiveness of pegylated interferon-al-pha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. Dig Dis Sci 2006; 51: 1619-1626.
11. Thomson BJ, Kwong G, Ratib S, et al. Trent HCV Study Group. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat 2008; 15: 271-278.
12. Lee SS, Bain VG, Peltekian K, et al. Canadian Pegasys Study Group. Treating chronic hepatitis C with pegylated in-terferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397-408.
13. Borroni G, Andreoletti M, Casiraghi MA, et al. Effectiveness of pegylated interferon/ribavirin combination in "real world" patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2008; 27: 790-797.
14. Witthöft T, Möller B, Wiedmann KH, et al. Safety, tolerabi-lity and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat 2007; 14: 788-796.
15. Zeuzem S. Heterogeneous virologic response rates to in-terferon-based therapy in patients with chronic hepati-tis C: who responds less well? Ann Intern Med 2004; 140: 370-381.
16. Shirakawa H, Matsumoto A, Joshita S, et al. Nagano Inter-feron Treatment Research Group Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-1760.
17. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroente-rol 2007; 102: 1383-1391.
18. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B, and C. J He-patol 2008; 49: 634-651.
19. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500-506.
20. Foster GR, Fried MW, Hadzyyannis SJ, Messinger D, et al. Prediction of sustained virological response in chronic hepatitis C patients treated with Peginterferon alfa 2a (40KD) and ribavirin. Scand J Gastroenterol 2007; 42: 247-255.
21. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterfe-ron and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
22. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al; Latino Study Group. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-267.
23. De Amici D, Klersy C, Ramajoli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Control Clin Trials 2000; 21: 103-114.